Basic Information | Post buying leads | Suppliers |
Molecule structure of Cinepazide maleate (CAS NO.26328-04-1):
IUPAC Name: (Z)-But-2-enedioic acid;1-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin-1-yl]-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
Molecular Formula: C26H35N3O9
Molecular Weight: 533.57 g/mol
Boiling Point: 637.8 °C at 760 mmHg
Flash Point: 339.5 °C
H-Bond Donor: 2
H-Bond Acceptor: 10
Rotatable Bond Count: 9
Exact Mass: 533.23733
MonoIsotopic Mass: 533.23733
Topological Polar Surface Area: 146
Heavy Atom Count: 38
Canonical SMILES: COC1=CC(=CC(=C1OC)OC)C=CC(=O)N2CCN(CC2)CC(=O)N3CCCC3.C(=CC(=O)O)C(=O)
Isomeric SMILES: COC1=CC(=CC(=C1OC)OC)C=CC(=O)N2CCN(CC2)CC(=O)N3CCCC3.C(=C\C(=O)O)\C(=O)
InChI: InChI=1S/C22H31N3O5.C4H4O4/c1-28-18-14-17(15-19(29-2)22(18)30-3)6-7-20(26)25-12-10-23(11-13-25)16-21(27)24-8-4-5-9-24;5-3(6)1-2-4(7)8/h6-7,14-15H,4-5,8-13,16H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
InChIKey: XSTJTOKYCAJVMJ-BTJKTKAUSA-N
EINECS: 247-613-1
Classification Code: Drug / Therapeutic Agent; Reproductive Effect
The uses of Cinepazide maleate (CAS NO.26328-04-1):
1. Cerebral vascular diseases: cerebral arteriosclerosis, a transient cerebral ischemia, cerebral thrombosis, cerebral embolism, cerebral hemorrhage and brain injury sequelae.
2. Cardiovascular disease, for arteriosclerosis, angina pectoris, myocardial infarction should be compatible with the relevant drug treatment.
3. Fundus vascular disease, ischemia caused by cochlear vestibular dysfunction, sudden deafness and tinnitus.
4. Microcirculation caused by diabetes (diabetic foot, diabetic retinopathy, etc.).
5. Other peripheral vascular disease: Thromboangiitis obliterans, arteritis, Raynaud's disease, lower extremity atherosclerosis and so on.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
mouse | LD50 | intravenous | 617mg/kg (617mg/kg) | BEHAVIORAL: TREMOR BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: ANTIPSYCHOTIC | Therapie. Vol. 29, Pg. 29, 1974. |
mouse | LD50 | oral | 1gm/kg (1000mg/kg) | BEHAVIORAL: TREMOR BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: ANTIPSYCHOTIC | Therapie. Vol. 29, Pg. 29, 1974. |
mouse | LD50 | subcutaneous | 946mg/kg (946mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 10, Pg. 407, 1979. | |
rat | LD50 | intravenous | 414mg/kg (414mg/kg) | BEHAVIORAL: TREMOR BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: ANTIPSYCHOTIC | Therapie. Vol. 29, Pg. 29, 1974. |
rat | LD50 | oral | 1310mg/kg (1310mg/kg) | BEHAVIORAL: TREMOR BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: ANTIPSYCHOTIC | Therapie. Vol. 29, Pg. 29, 1974. |
rat | LD50 | subcutaneous | 710mg/kg (710mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 10, Pg. 407, 1979. |
Moderately toxic by ingestion, subcutaneous, and intravenous routes. An experimental teratogen. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of NOx.
Cinepazide maleate (CAS NO.26328-04-1) is also named as 1-((1-Pyrrolidinylcarbonyl)methyl)-4-(3,4,5-trimethoxycinnamoyl)piperazine maleate ; 1-(4-((3',4',5'-Trimethoxycinnamoyl)-1-piperazinyl)acetyl)pyrrolidine maleate ; 4-(3,4,5-Trimethoxycinnamoyl)-1-(1-pyrrolidinyl)carbonylmethylpiperazine maleate ; Brendil ; MD 67350 ; Maleate de cinepazide ; Maleate de cinepazide [French] ; NSC 291562 ; Vasodistal .